论文部分内容阅读
目的评价拉米夫定治疗不同临床类型慢性乙型肝炎病毒（HBV）感染的近期疗效。方法口服拉米夫定150mg，每日1次，连服6个月，治疗慢性乙型肝炎病人40例，肝炎肝硬化18例，慢性重型肝炎10例。观察其临床、生物化学、血清学和病毒学改变。结果（1）慢性乙型肝炎病情缓解。对照组病毒血症持续，27．5％病人于随访期内肝炎复发（P＜0．001）。同时观察拉米夫定联用干扰素治疗病人20例，未见提高疗效。（2）肝炎肝硬化病情渐趋稳定，肝功能好转，Child—Pugh积分下降。（3）慢性重型肝炎除2例服药不足3个月死亡外，余8例病情缓解，随着肝功能改善，生活质量显著好转。结论拉米夫定适用于治疗慢性乙型肝炎，对处于HBV复制状态的肝硬化和重型肝炎也有效。
Objective To evaluate the short-term efficacy of lamivudine in the treatment of different clinical types of chronic hepatitis B virus (HBV) infection. Methods Oral Lamivudine 150mg, once daily, even for 6 months, treatment of chronic hepatitis B patients 40 cases, hepatitis cirrhosis 18 cases, 10 cases of chronic severe hepatitis. Observe its clinical, biochemical, serological and virological changes. Results (1) Chronic hepatitis B remission. In the control group, viremia persisted, with 27.5% of patients relapsed during the follow-up period (P <0.001). At the same time observed lamivudine combined with interferon treatment of patients in 20 cases, no improvement in efficacy. (2) Hepatitis cirrhosis gradually stable, liver function improved, Child-Pugh integral decreased. (3) In addition to two cases of chronic severe hepatitis died of medication less than 3 months, the remaining 8 cases of remission, with the improvement of liver function, quality of life significantly improved. Conclusion Lamivudine is suitable for the treatment of chronic hepatitis B and is also effective for cirrhosis and severe hepatitis in HBV replication status.